Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of IVIEW-1201 to treat and prevent COVID-19 infections in the eye

Next Previous
Structure search
Last 5 Searches
Advanced search AskAdis AI Search New
Trial Profile

A clinical trial of IVIEW-1201 to treat and prevent COVID-19 infections in the eye

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2020

At a glance

  • Drugs Povidone iodine (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use

Most Recent Events

  • 07 Apr 2020 New trial record
  • 05 Apr 2020 According to an iView Therapeutics media release, the company's IVIEW-1201, a PVP-I gel-forming ophthalmic drop used to treat Acute Adenovirus Conjunctivitis could potentially be used to treat and prevent COVID-19 infections in the eye. The company has been working closely with China's CDE since January 2020 to initiate clinical trials.

Trial Overview

Purpose

This study will evaluate IVIEW-1201, a PVP-I gel-forming ophthalmic drop to treat and prevent COVID-19 infections in the eye.

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections prevention, treatment -

Subjects

  • Subject Type patients
  • Sex male & female

Trial Details

Organisations

  • Affiliations iView Therapeutics

Trial Dates

Other Details

  • Design prospective
  • Phase of Trial Phase II
  • Location China
  • Focus Therapeutic Use

Interventions

Drugs Route Formulation Target
Povidone iodine
Primary Drug
 		Ophthalmic Drops Bacterial protein

IVIEW-1201

Trial History

Event Date Event Type Comment
07 Apr 2020 New trial record New trial record Updated 07 Apr 2020
05 Apr 2020 Other trial event According to an iView Therapeutics media release, the company's IVIEW-1201, a PVP-I gel-forming ophthalmic drop used to treat Acute Adenovirus Conjunctivitis could potentially be used to treat and prevent COVID-19 infections in the eye. The company has been working closely with China's CDE since January 2020 to initiate clinical trials. Updated 07 Apr 2020

References

  1. iView Therapeutics. iVIEW is developing a safe, non-toxic and long-acting Povidone Iodine nasal spray for the prevention and treatment of COVID-19 infection to curb the COVID-19 spread. Media-Rel 2020;.

    Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG
Back to top